<code id='ECB1DEE94D'></code><style id='ECB1DEE94D'></style>
    • <acronym id='ECB1DEE94D'></acronym>
      <center id='ECB1DEE94D'><center id='ECB1DEE94D'><tfoot id='ECB1DEE94D'></tfoot></center><abbr id='ECB1DEE94D'><dir id='ECB1DEE94D'><tfoot id='ECB1DEE94D'></tfoot><noframes id='ECB1DEE94D'>

    • <optgroup id='ECB1DEE94D'><strike id='ECB1DEE94D'><sup id='ECB1DEE94D'></sup></strike><code id='ECB1DEE94D'></code></optgroup>
        1. <b id='ECB1DEE94D'><label id='ECB1DEE94D'><select id='ECB1DEE94D'><dt id='ECB1DEE94D'><span id='ECB1DEE94D'></span></dt></select></label></b><u id='ECB1DEE94D'></u>
          <i id='ECB1DEE94D'><strike id='ECB1DEE94D'><tt id='ECB1DEE94D'><pre id='ECB1DEE94D'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:3
          Grail

          Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

          Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

          advertisement

          It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more
          Medical experts are missing from AI regulatory conversations
          Medical experts are missing from AI regulatory conversations

          SenateMajorityLeaderChuckSchumerinJuneannouncedtheSAFEInnovationframeworkto“supportresponsiblesystem

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

          1:48AmandescribedinabailapplicationasGilgoBeachmurdersuspectRexA.Heuermannappearsinastillimagefromsu